Cited by 184Pancreatic and Hepatic Oncology ResearchMRI in cancer diagnosisMathematical Biology Tumor Growth

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Transport properties of pancreatic cancer describe gemcitabine delivery and response

Open access

Koay, Eugene J., Truty, Mark J., Cristini, Vittorio, Thomas, Ryan M., Chen, Rong, Chatterjee, Deyali, Kang, Ya’an, Bhosale, Priya R., Tamm, Eric P., Crane, Christopher H., Javle, Milind, Katz, Matthew H., Gottumukkala, Vijaya N., Rozner, Marc A., Shen, Haifa, Lee, Jeffery E., Wang, Huamin, Chen, Yuling, Plunkett, William, Abbruzzese, James L., Wolff, Robert A., Varadhachary, Gauri R., Ferrari, Mauro, Fleming, Jason B.·2014·Journal of Clinical Investigation

DOI 10.1172/jci73455PMC PMC3973100

Open this paper in CoChat — free account

Abstract

BACKGROUND: The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) is partly ascribed to ineffective delivery of chemotherapy to cancer cells. We hypothesized that physical properties at vascular, extracellular, and cellular scales influence delivery of and response to gemcitabine-based therapy. METHODS: We developed a method to measure mass transport properties during routine contrast-enhanced CT scans of individual human PDAC tumors. Additionally, we evaluated gemcitabine infusion during PDAC resection in 12 patients, measuring gemcitabine incorporation into tumor DNA and correlating its uptake with human equilibrative nucleoside transporter (hENT1) levels, stromal reaction, and CT-derived mass transport properties. We also studied associations between CT-derived transport properties and clinical outcomes in patients who received preoperative gemcitabine-based chemoradiotherapy for resectable PDAC. RESULTS: Transport modeling of 176 CT scans illustrated striking differences in transport properties between normal pancreas and tumor, with a wide array of enhancement profiles. Reflecting the interpatient differences in contrast enhancement, resected tumors exhibited dramatic differences in gemcitabine DNA incorporation, despite similar intravascular pharmacokinetics. Gemcitabine incorporation into tumor DNA was inversely related to CT-derived transport parameters and PDAC stromal score, after accounting for hENT1 levels. Moreover, stromal score directly correlated with CT-derived parameters. Among 110 patients who received preoperative gemcitabine-based chemoradiotherapy, CT-derived parameters correlated with pathological response and survival. CONCLUSION: Gemcitabine incorporation into tumor DNA is highly variable and correlates with multiscale transport properties that can be derived from routine CT scans. Furthermore, pretherapy CT-derived properties correlate with clinically relevant endpoints. TRIAL REGISTRATION: Clinicaltrials.gov NCT01276613. FUNDING: Lustgarten Foundation (989161), Department of Defense (W81XWH-09-1-0212), NIH (U54CA151668, KCA088084).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci73455

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Pancreatic cancer
Li, D., Xie, K., Wolff, R. A., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,731
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,706
Intravenous Contrast Medium Administration and Scan Timing at CT: Considerations and Approaches
Bae, K. T. (2010) · Radiology · doi:10.1148/radiol.10090908 · Cited by 1,068
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Varadhachary, G. R., Tamm, E. P., Abbruzzese, J. L., Xiong, H. Q., Crane, C. H., Wang, H., Lee, J. E., Pisters, P. W. T., Evans, D. B., & Wolff, R. A. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.011 · Cited by 876
Transport of molecules across tumor vasculature
Jain, R. K. (1987) · Cancer and Metastasis Reviews · doi:10.1007/bf00047468 · Cited by 869
Stromal biology and therapy in pancreatic cancer
Neeße, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2010) · Gut · doi:10.1136/gut.2010.226092 · Cited by 780

Flagged first, then by citations

Show all 42 references

Sorted by citations

Items 101–184 of 184

PanIN or IPMN? Redefining Lesion Size in 3 Dimensions
Kiemen, A. L., Dequiedt, L., Shen, Y., Zhu, Y., Matos-Romero, V., Forjaz, A., Campbell, K., Dhana, W., Cornish, T. C., Braxton, A. M., et al. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002245 · Cited by 18
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
Butner, J. D., Martin, G. V., Wang, Z., Corradetti, B., Mauro Ferrari, B., Esnaola, N., Chung, C., Hong, D. S., Welsh, J., Hasegawa, N., et al. (2021) · eLife · doi:10.7554/elife.70130 · Cited by 18
Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
Stock, K., Steinestel, K., Wiesch, R., Mikesch, J., Hansmeier, A., Trautmann, M., Beller, N., Rehkämper, J., Wardelmann, E., Heitkötter, B., et al. (2017) · BioMed Research International · doi:10.1155/2017/2847303 · Cited by 18
Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma
Suzuki, R., Asama, H., Waragai, Y., Takagi, T. J., Hikichi, T., Sugimoto, M., Konno, N., Watanabe, K., Nakamura, J., Kikuchi, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23377 · Cited by 18
Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity
McCarthy, G. A., Niro, R. D., Finan, J. M., Jain, A., Guo, Y., Wyatt, C. R., Guimarães, A. R., Waugh, T., Keith, D., Morgan, T. K., et al. (2023) · NAR Cancer · doi:10.1093/narcan/zcad016 · Cited by 17
Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer
Kang, J. H., Lee, S. S., Kim, J. H., Byun, J. H., Kim, H. J., Yoo, C., Kim, K., Ryoo, B., & Kim, S. C. (2020) · European Radiology · doi:10.1007/s00330-020-07134-8 · Cited by 17
Enhancement pattern mapping technique for improving contrast‐to‐noise ratios and detectability of hepatobiliary tumors on multiphase computed tomography
Park, P. C., Choi, G. W., Zaid, M., Elganainy, D., Smani, D. A., Tomich, J., Samaniego, R., Ma, J., Tamm, E. P., Beddar, S. A., et al. (2019) · Medical Physics · doi:10.1002/mp.13769 · Cited by 16
Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection
Zaid, M., Elganainy, D., Dogra, P., Dai, A., Widmann, L., Fernandes, P., Wang, Z., Peláez, M. J., Ruiz-Ramírez, J., Singhi, A. D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.596931 · Cited by 16
Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance
Zhang, Y.-J., Wen, C., Qin, Y., Tang, X.-M., Shi, M.-M., Shen, B., & Fang, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.6026 · Cited by 15
Cancer and Cardiovascular Disease: The Conjoined Twins
Zmaili, M. A., Alzubi, J. M., Alkhayyat, M. M., Albakri, A. A., Alkhalaileh, F., Longinow, J., & Moudgil, R. (2024) · Cancers · doi:10.3390/cancers16081450 · Cited by 18
Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis
Vos, L. J., Yusuf, D., Lui, A. G. A., Abdelaziz, Z., Ghosh, S., Spratlin, J. L., & Mackey, J. R. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00240 · Cited by 14
Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging
Jungmann, F., Kaissis, G. A., Ziegelmayer, S., Harder, F., von Schilling, C., Yen, H.-Y., Steiger, K., Weichert, W., Schirren, R., Demir, I. E., et al. (2021) · Cancers · doi:10.3390/cancers13092069 · Cited by 14
Editorial Special Section on Multiscale Cancer Modeling
Wang, Z., & Maini, P. K. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2655439 · Cited by 15
Mass release curves as the constitutive curves for modeling diffusive transport within biological tissue
Kojić, M., Milošević, M., Kojić, N., Koay, E. J., Fleming, J. B., Mauro Ferrari, B., & Žiemys, A. (2016) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2016.06.026 · Cited by 13
Dietary approach to attenuate human pancreatic cancer growth and migration with innoxiousness
Lee, J., Lee, J., Kim, M., & Kim, J. H. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2016.12.032 · Cited by 13
Molecular tests for prediction of tumor sensitivity to cytotoxic drugs
Имянитов, Е. Н., & Iyevleva, A. G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.021 · Cited by 12
Baseline CT-based Radiomic Features Aid Prediction of Nodal Positivity after Neoadjuvant Therapy in Pancreatic Cancer
Elsherif, S. B., Javadi, S., Le, O., Lamba, N., Katz, M. H. G., Tamm, E. P., & Bhosale, P. (2022) · Radiology Imaging Cancer · doi:10.1148/rycan.210068 · Cited by 12
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer
Gautam, S. K., Dalal, V., Sajja, B. R., Gupta, S., Gulati, M., Dwivedi, N. V., Aithal, A., Cox, J. L., Rachagani, S., Liu, Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215801 · Cited by 12
Transport Oncophysics in silico, in vitro, and in vivo
Koay, E. J., & Mauro Ferrari, B. (2014) · Physical Biology · doi:10.1088/1478-3975/11/6/060201 · Cited by 12
Upregulation of DUSP14 Affects Proliferation, Invasion and Metastasis, Potentially via Epithelial–Mesenchymal Transition and Is Associated with Poor Prognosis in Pancreatic Cancer
Wei, Y., Wang, G., Wang, C., Zhou, Y., Zhang, J., & Xu, K. L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s240040 · Cited by 12
Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma
Wei, D., Zaid, M., Katz, M. H. G., Prakash, L. R., Kim, M. P., Tzeng, C.-W. D., Lee, J. E., Agrawal, A., Rashid, A., Wang, H., et al. (2020) · Pancreatology · doi:10.1016/j.pan.2020.11.003 · Cited by 12
Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+CAFs in intrahepatic cholangiocarcinoma
Li, J., Wu, X. F., Ni, X., Li, Y.-X., Xu, L., Hao, X., Zhao, W., Zhu, X., & Yin, X. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1213 · Cited by 11
Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic
Tang, C. Z., Hess, K. R., Jardim, D. L. F., Gagliato, D. D. M., Tsimberidou, A. M., Falchook, G. S., Fu, S., Jankú, F., Naing, A., Piha-Paul, S. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1582 · Cited by 11
In vitro and in vivo antitumor activity of gemcitabine loaded thermosensitive liposomal nanoparticles and mild hyperthermia in pancreatic cancer.
Affram, K., Udofot, O., Cat, A., & Agyare, E. (2015) · PubMed · Cited by 11
Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer
Emori, T., Ashida, R., Tamura, T., Kawaji, Y., Hatamaru, K., Itonaga, M., Yamashita, Y., Shimokawa, T., Higashino, N., Ikoma, A., et al. (2022) · Pancreatology · doi:10.1016/j.pan.2022.04.005 · Cited by 11
Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines.
Affram, K., Udofot, O., & Agyare, E. (2015) · PubMed · Cited by 11
Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer
Holyoake, D., Robinson, M., Grose, D. B., McIntosh, D., Sebag‐Montefiore, D., Radhakrishna, G., Patel, N., Partridge, M., Mukherjee, S., & Hawkins, M. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.08.001 · Cited by 10
Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma
Rosemurgy, A. S., Ross, S. B., Vitulli, P. L., Malek, R., Li, J., & Agah, R. (2017) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2017.0011 · Cited by 10
Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy
Kai, M., Žiemys, A., Liu, Y. T., Kojić, M., Mauro Ferrari, B., & Yokoi, K. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.05.011 · Cited by 9
PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer
Douglas, J. E., Liu, S., Ma, J., Wolff, R. A., Pant, S., Maitra, A., Tamm, E. P., Bhosale, P., Katz, M. H. G., Varadhachary, G. R., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09095-7 · Cited by 9
A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer
Lin, H., Hu, C., Zheng, S., Zhang, X., Chen, R., & Zhou, Q. (2021) · Aging · doi:10.18632/aging.202922 · Cited by 9
Sustained degradation of hyaluronic acid using an in situ forming implant
Hopkins, K., Buno, K., Romick, N., dos Santos, A., Tinsley, S. L., Wakelin, E., Kennedy, J., Ladisch, M. R., Allen-Petersen, B. L., & Solorio, L. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac193 · Cited by 8
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model
Narayanan, J. S. S., Vicente, D. A., Ray, P., Chai, L. F., Erdem, S., Carr, M. J., Capacio, B. A., Cox, B. F., Jaroch, D., Katz, S. C., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.04.059 · Cited by 7
Pancreatic Ductal Adenocarcinoma: Interface Enhancement Gradient Measured on Dual-Energy CT Images Improves Prognostic Evaluation
Amer, A. M., Li, Y., Summerlin, D. S., Burgan, C. M., McNamara, M. M., Smith, A. D., & Morgan, D. E. (2020) · Radiology Imaging Cancer · doi:10.1148/rycan.2020190074 · Cited by 7
A Novel Tumor Progression Prediction Method for Multimode Ablation Treatment
Wang, X., Li, W., Zhang, K., Sun, J., Yang, J., Zhang, A., & Xu, L. X. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2021.3116607 · Cited by 7
Oncology and mechanics: Landmark studies and promising clinical applications
Urcun, S., Lorenzo, G., Baroli, D., Rohan, P., Sciumè, G., Skalli, W., Lubrano, V., & Bordas, S. (2022) · Advances in applied mechanics · doi:10.1016/bs.aams.2022.05.003 · Cited by 8
Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model: A Mechanism Recruiting the Vasa Vasorum for Localized Therapies
Farsad, K., Novelli, P. M., Laing, C., Gandhi, R. T., Cynamon, J., López, C. S., Stempinski, E., Strasser, R., & Agah, R. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.03.016 · Cited by 6
Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer
Rong, Z., Yang, J., Liu, J., Meng, Q., Hua, J., Tan, Z., Zhang, B., Liu, Y., Du, Q., Wang, W., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002242 · Cited by 6
Emerging Challenges to Cellular Therapy of Cancer
Lulla, P., & Brenner, M. K. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000637 · Cited by 6
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
Zhong, J., Zheng, Q., Gao, E., Dong, Z., Zhao, J., An, T., Wu, M., Zhuo, M., Wang, Y., Li, J., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12581 · Cited by 6
Imaging and Endoscopic Approaches to Pancreatic Cancer
Rosenthal, M. H., Lee, A., & Jajoo, K. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.008 · Cited by 6
Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization
Heid, I., Trajkovic‐Arsic, M., Lohöfer, F. K., Kaissis, G. A., Harder, F. N., Mayer, M., Topping, G. J., Jungmann, F., Crone, B., Wildgruber, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05930-6 · Cited by 5
The influence of soluble fragments of extracellular matrix (ECM) on tumor growth and morphology
Nargis, N. N., Aldredge, R. C., & Guy, R. D. (2017) · Mathematical Biosciences · doi:10.1016/j.mbs.2017.11.014 · Cited by 5
ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer
Li, Y., Wang, H., Chen, L., Gong, Y., Zheng, D., Li, F., Wu, C., He, Z., & Yu, C. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08061-6 · Cited by 6
Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH‐Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma PDX Model
Huang, C., Dai, C., Liu, Q., Chen, S., Guo, Y., Wang, J., Zheng, A., Huang, X., Wu, J., & Yin, X. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503694 · Cited by 4
Lapathoside A Isolated fromFagopyrum esculentumInduces Apoptosis in Human Pancreatic Cancer Cells
Kang, M. S., Ham, Y., Oh, D.-J., Jung, Y., Han, S.-I., & Kim, J. H. (2021) · Anticancer Research · doi:10.21873/anticanres.14826 · Cited by 4
Seed- and Soil-Dependent Differences in Murine Breast Tumor Microenvironments Dictate Anti-PD-L1 IgG Delivery and Therapeutic Efficacy
Liu, Y. T., Goel, S., Kai, M., Moran-Guerrero, J. A., Nguyen, T. U., Mai, J., Shen, H., Žiemys, A., & Yokoi, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040530 · Cited by 4
Reshaping the critical role of surgeons in oncology research
Jones, R. P., Are, C., Hugh, T. J., Grünhagen, D. J., Xu, J., Balch, C. M., & Poston, G. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0149-1 · Cited by 4
Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma
Goto, S., Yoshizawa, T., Ishido, K., Seino, H., Morohashi, S., Ogasawara, H., Kubota, S., Ogasawara, K., Nakamura, A., Hakamada, K., et al. (2023) · Oncology Reports · doi:10.3892/or.2023.8498 · Cited by 3
Neoadjuvant Chemotherapy in Pancreatic Cancer
Hank, T. P., Büchler, M. W., & Neoptolemos, J. P. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2020.6273 · Cited by 3
Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer
Wang, C. X., Elganainy, D., Zaid, M., Butner, J. D., Agrawal, A., Nizzero, S., Minsky, B. D., Holliday, E. B., Taniguchi, C. M., Smith, G. L., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.04.044 · Cited by 3
Stochastic model for computer simulation of the number of cancer cells and lymphocytes in homogeneous sections of cancer tumorsPreprint
Castellanos-Moreno, A., Castellanos-Jaramillo, A., Corella-Madueño, A., Gutiérrez-López, S., & Rosas-Burgos, R. A. (2014) · arXiv (Cornell University) · doi:10.48550/arxiv.1410.3768 · Cited by 3
Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model
Li, X., Liu, Y., Zhou, F., Guo, W., Chen, G., Tao, J., Huang, J., Qiu, J., Chen, H., Ren, B. X., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217751 · Cited by 4
Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings
Mattioli, S. L., Dogra, P., Longobardi, F., Casiello, G., Apparente, L., Detta, N., Novelli, R., Aramini, A., Cattani, F., Antonangeli, M. I., et al. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf250 · Cited by 2
Surgical intervention strategies for tumor microenvironment (TME) associated therapeutic resistance
Chen, D., Wang, H., & Che, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-04092-9 · Cited by 2
LINC01963 promotes pancreatic ductal adenocarcinoma proliferation via METTL3/IGF2BP2 axis-mediated m⁶A modification of c-Myc
Liu, Q., Li, R., Liu, B., Liu, H., Shi, X., Yin, X., Ju, X., Zhang, S. W., Wang, J., Zhang, Y., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03650-5 · Cited by 2
Personalized Therapy of Cancer
Jain, K. K. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2553-7_10 · Cited by 2
Personalized Management of Cancers of Various Organs/Systems
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_21 · Cited by 2
Pressure-Enabled Drug Delivery Approach in the Pancreas with Retrograde Venous Infusion of Lipiodol with Ex Vivo Analysis
Arepally, A., Chomas, J. E., Katz, S. C., Jaroch, D., Kolli, K. P., Prince, E. A., & Liddell, R. P. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02625-z · Cited by 2
Contrast enhanced CT and MRI interchangeably reflect tumor characteristics in murine pancreatic cancer
Würfel, L., Niehaus, P., Topping, G. J., Semina, M., Mittelhäuser, M., Kossatz, S., Lesina, M., Lohöfer, F. K., Schilling, F., Kärst, U., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-56008-4 · Cited by 1
Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma
Rosemurgy, A. S., Ross, S. B., Vitulli, P. L., Malek, R., Li, J., & Agah, R. (2017) · Journal of Pancreatic Cancer · doi:10.1089/crpc.2017.0011 · Cited by 1
Emerging Technologies for the Diagnosis and Treatment of Pancreatic Cancer
Swierczewska, M., Козлов, С. В., & Adiseshaiah, P. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00022-3 · Cited by 1
Starvation Induced Autophagy Promotes The Progression of Bladder Cancer By LDHA Mediated Metabolic ReprogrammingPreprint
Li, T., Tong, H., Yin, H., Luo, Y., Zhu, J., Qin, Z., Yin, S., & He, W. (2021) · Research Square · doi:10.21203/rs.3.rs-795270/v1 · Cited by 1
Adjuvant Chemotherapy in Pancreatic Cancer
Jones, R. P., Ghaneh, P., & Neoptolemos, J. P. (2018) · doi:10.1002/9781119188421.ch113 · Cited by 1
Adjuvant Chemotherapy in Pancreatic Cancer
Mann, K., Jones, R. P., Ghaneh, P., & Neoptolemos, J. P. (2023) · doi:10.1002/9781119876007.ch148 · Cited by 1
Computational Approaches for Multiscale Modeling
Wang, Z., Vittorio Cristini, C., & Deisboeck, T. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.40013-1
Effects of vascularization on cancer nanochemotherapy outcomes
Paiva, L. R., Ferreira, S. C., & Martins, M. L. (2016) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2016.02.065
Development of a diffusion-based mathematical model for predicting chemotherapy effects
Wang, Z., Kerketta, R., Chuang, Y.-L., & Vittorio Cristini, C. (2014) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2014.6944125
Gemcitabine Resistance Elicits a Calcium Dependent Epigenetic Reprogramming in Pancreatic Cancer
Kutschat, A. P. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8475
Präklinische Analyse von epithelialen und stromalen Markern in einem transgenen Mausmodell für Pankreaskarzinome
Klein, L. (2021) · doi:10.53846/goediss-8402
Multiscale hierarchical models for diffusion in composite media and tissue
Kojić, M., Milošević, M., & Žiemys, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88472-3.00005-0
Application of Kojic transport model (KTM) to convective-diffusive transport and electrophysiology in tissue and capillaries
Kojić, M., Milošević, M., & Žiemys, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88472-3.00008-6
Imaging-Based Biomarkers for Pancreatic Cancer
Thomas, J., Douglas, J. E., & Koay, E. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-05724-3_19
Data from Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic
Tang, C. Z., Hess, K. R., Jardim, D. L. F., Gagliato, D. D. M., Tsimberidou, A. M., Falchook, G. S., Fu, S., Jankú, F., Naing, A., Piha-Paul, S. A., et al. (2023) · doi:10.1158/1078-0432.c.6523040
Data from Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic
Tang, C. Z., Hess, K. R., Jardim, D. L. F., Gagliato, D. D. M., Tsimberidou, A. M., Falchook, G. S., Fu, S., Jankú, F., Naing, A., Piha-Paul, S. A., et al. (2023) · doi:10.1158/1078-0432.c.6523040.v1
Stromal Activation Induces the Switch of Metabolic Subtype in Pancreatic CancerPreprint
Rong, Z., Yang, J., Liu, J., Meng, Q., Hua, J., Tan, Z., Zhang, B., Liu, Y., Du, Q., Wang, W., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4810683
Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery
Oikawa, S., Mitomi, H., Murai, S., Nakayama, A., Chiba, S., Nishihara, S., Ishii, Y., Yamochi, T., & Yoshida, H. (2025) · Current Oncology · doi:10.3390/curroncol32100578
Additional file 1 of PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer
Douglas, J. E., Liu, S., Ma, J., Wolff, R. A., Pant, S., Maitra, A., Tamm, E. P., Bhosale, P., Katz, M. H. G., Varadhachary, G. R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.17799618
Additional file 1 of Starvation induced autophagy promotes the progression of bladder cancer by LDHA mediated metabolic reprogramming
Li, T., Tong, H., Yin, H., Luo, Y., Zhu, J., Qin, Z., Yin, S., & He, W. (2021) · Figshare · doi:10.6084/m9.figshare.16946377
A nomogram for predicting the disease-free survival of patients with pancreatic ductal adenocarcinoma
Pan, Y., Wang, X.-J., Zhou, J.-P., Yu, J., & Yu, R.-S. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02301-7
Rôle d'un antagoniste de la nucléoline de surface : le N6L, sur la régulation de l’angiogenèse tumorale dans le modèle de l'adénocarcinome ductale pancréatique
Gilles, M.-E. (2015) · theses.fr (ABES) · doi:10.70675/252c9d25z3baaz4d5bzb204z51782ed7adf7
Etude et inhibition de l'activation endothéliale au cours de l'angiogenèse
Cossutta, M. (2017) · theses.fr (ABES) · doi:10.70675/b2ab1c80zb5caz47c4za53bz83c66b494fda
Engineered αvβ6-targeting peptide‒BSH conjugates for boron neutron capture therapy of pancreatic ductal adenocarcinoma
Li, L., Gao, X., Zhang, S., Wang, X., Chen, X., Miao, Y., Zhang, T., Yang, M., Liu, C., Liang, T., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.012
PARP inhibitors and the tumor micro-environment: Bidirectional crosstalk, resistance mechanisms, and therapeutic opportunities
Ding, Y., Wang, Y., Lin, Y., Zhu, C., Li, K., & Feng, W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105566

Authors: Koay, E. J., Truty, M. J., Cristini, V., Thomas, R. M., Chen, R., Chatterjee, D., Kang, Y., Bhosale, P. R., Tamm, E. P., Crane, C. H., Javle, M., Katz, M. H., Gottumukkala, V. N., Rozner, M. A., Shen, H., Lee, J. E., Wang, H., Chen, Y., Plunkett, W., Abbruzzese, J. L., Wolff, R. A., Varadhachary, G. R., Ferrari, M., & Fleming, J. B.
Affiliations: Houston Methodist (US)
University of Florida (US)
The University of Texas MD Anderson Cancer Center (US)
Duke University (US)
Corresponding author: Fleming, Jason B.
ORCID: Koay, Eugene J.
Truty, Mark J.
Thomas, Ryan M.
Chen, Rong
Chatterjee, Deyali
Kang, Ya’an
Bhosale, Priya R.
Tamm, Eric P.
Crane, Christopher H.
Javle, Milind
Katz, Matthew H.
Gottumukkala, Vijaya N.
Shen, Haifa
Lee, Jeffery E.
Wang, Huamin
Plunkett, William
Abbruzzese, James L.
Wolff, Robert A.
Fleming, Jason B.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2014-03-10
Volume: 124
Issue: 4
Pages: 1525-1536
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci73455
PMC: PMC3973100
OpenAlex: W2070252009
Cited by: 184
References: 42
Citations by year: 2026: 5 · 2025: 8 · 2024: 4 · 2023: 10 · 2022: 13 · 2021: 22 · 2020: 17 · 2019: 15 · 2018: 17 · 2017: 26 · 2016: 17 · 2015: 21 · 2014: 8
FWCI: 11.57
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Investigation (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Science Foundation (1263742)
U.S. Department of Defense (W81XWH, W81XWH0910212)
Lustgarten Foundation (989161)
National Institutes of Health (W81XWH)
U.S. Public Health Service (K12 KCA088084)
National Cancer Institute (U54CA151668, U54CA149196, U54CA143837, P30CA016672, K12CA088084)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords: pancreatic ductal adenocarcinoma, gemcitabine, mass transport properties, contrast-enhanced CT, tumor stroma, hENT1, chemotherapy delivery, chemoradiotherapy, neoadjuvant chemoradiotherapy, pathological response, treatment response prediction
MeSH terms: Gemcitabine, Aged, Antimetabolites, Antineoplastic, Biological Transport, Active, Deoxycytidine, DNA, Neoplasm, Female, Humans, Male, Middle Aged, Models, Biological, Pancreatic Neoplasms, Prognosis, Prospective Studies, Tomography, X-Ray Computed, DNA Adducts, Carcinoma, Pancreatic Ductal, Equilibrative Nucleoside Transporter 1, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Transport properties of pancreatic cancer describe gemcitabine delivery and response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks